Theravance Biopharma Inc Working Capital to Net Assets Ratio
Theravance Biopharma Inc working capital to net assets ratio. Theravance Biopharma Inc (0TB) has a Working Capital to Net Assets ratio of 136.4% as of September 2025. Working capital of €317.29 Million (current assets of €354.70 Million minus current liabilities of €37.41 Million) is measured against net assets of €232.68 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Theravance Biopharma Inc (2014–2024)
Working capital to net assets ratio of Theravance Biopharma Inc from 2014 to 2024. This chart shows how Theravance Biopharma Inc's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2014 to 2024. As of September 2025, the ratio stands at 136.4%, reflecting working capital of €317.29 Million against net assets of €232.68 Million EUR. Explore investment intensity of Theravance Biopharma Inc to see how much of total assets are deployed in long-term investments.
Theravance Biopharma Inc Working Capital to Net Assets Ratio by Year (2014–2024)
Theravance Biopharma Inc working capital to net assets ratio by year from 2014 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Theravance Biopharma Inc from 2014 to 2024, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 0TB total asset value.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 73.5% | €128.98 Million | €175.54 Million | €161.07 Million | €32.09 Million | ▲ +22.4 pp |
| 2023 | 51.1% | €108.77 Million | €213.00 Million | €133.54 Million | €24.77 Million | ▼ -22.4 pp |
| 2022 | 73.5% | €324.75 Million | €441.80 Million | €353.46 Million | €28.71 Million | ▲ +130.0 pp |
| 2021 | -56.5% | €191.28 Million | €-338.57 Million | €249.87 Million | €58.59 Million | ▲ +32.3 pp |
| 2020 | -88.8% | €269.77 Million | €-303.75 Million | €393.34 Million | €123.57 Million | ▲ +12.5 pp |
| 2019 | -101.3% | €226.78 Million | €-223.84 Million | €338.49 Million | €111.70 Million | ▲ +740.5 pp |
| 2018 | -841.8% | €434.27 Million | €-51.59 Million | €532.82 Million | €98.55 Million | ▼ -1116.3 pp |
| 2017 | 274.5% | €316.20 Million | €115.18 Million | €378.75 Million | €62.55 Million | ▲ +137.7 pp |
| 2016 | 136.8% | €479.24 Million | €350.23 Million | €528.50 Million | €49.27 Million | ▲ +59.5 pp |
| 2015 | 77.3% | €188.00 Million | €243.06 Million | €237.47 Million | €49.47 Million | ▼ -3.4 pp |
| 2014 | 80.8% | €234.11 Million | €289.79 Million | €275.37 Million | €41.26 Million | — |